IMA

ImageneBio Inc

Apr 02 • 04:00PM ET

4.97

-0.08 -1.58 %

Healthcare • Biotechnology • USA • NASD

Index	-	P/E	-	EPS (ttm)	-6.45	Insider Own	37.74%	Shs Outstand	10.65M	Perf Week	-7.96%
Market Cap	55.59M	Forward P/E	-	EPS next Y	-2.41	Insider Trans	0.38%	Shs Float	6.96M	Perf Month	-19.19%
Enterprise Value	-69.77M	PEG	-	EPS next Q	-0.67	Inst Own	27.10%	Short Float	5.43%	Perf Quarter	-27.97%
Income	-43.92M	P/S	-	EPS this Y	69.61%	Inst Trans	-8.27%	Short Ratio	10.19	Perf Half Y	-41.60%
Sales	0.00M	P/B	0.42	EPS next Y	17.63%	ROA	-29.25%	Short Interest	0.38M	Perf YTD	-27.97%
Book/sh	11.91	P/C	0.41	EPS next 5Y	30.86%	ROE	-33.25%	52W High	18.00 -72.39%	Perf Year	-66.87%
Cash/sh	12.10	P/FCF	-	EPS past 3/5Y	24.93% 8.22%	ROIC	-31.18%	52W Low	3.94 26.14%	Perf 3Y	-88.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-62.86% -38.64%	Gross Margin	-	Volatility	14.09% 8.18%	Perf 5Y	-98.41%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	47.28%	Oper. Margin	-	ATR (14)	0.45	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.49	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	28.05	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	12.49	EPS Q/Q	72.77%	SMA20	-11.40%	Beta	0.59	Target Price	16.00
Payout	-	Debt/Eq	0.08	Sales Q/Q	-	SMA50	-21.99%	Rel Volume	0.39	Prev Close	5.05
Employees	15	LT Debt/Eq	0.06	Earnings	Mar 10 BMO	SMA200	-46.98%	Avg Volume	37.10K	Price	4.97
IPO	Mar 26, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	24.75% -	Trades		Volume	14,549	Change	-1.58%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-25-25	Resumed	Wedbush	Underperform	$2
Oct-24-25	Initiated	Leerink Partners	Outperform	$30

Mar-17-26 04:30PM	ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-10-26 08:00AM	ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update (GlobeNewswire)
Feb-26-26 08:00AM	ImageneBio to Participate in Leerink Global Healthcare Conference (GlobeNewswire)
Feb-10-26 07:00AM	ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer (GlobeNewswire)
Nov-12-25 07:15AM	ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team (GlobeNewswire)
08:30AM	Loading…
Nov-06-25 08:30AM	ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences (GlobeNewswire)
Aug-05-25 09:55AM	Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade (Zacks)
Aug-01-25 04:15PM	ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-25-25 11:00AM	Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million (GlobeNewswire)

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. It focuses on the development of new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company was founded in February 2016, and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SLATTERY JOSEPH P	Director	Dec 24 '25	Buy	5.99	16,000	95,840	16,000	Dec 29 04:46 PM
Bonita David P	Director	Jul 25 '25	Buy	29.90	83,611	2,499,969	287,885	Jul 30 04:51 PM
Stampacchia Otello	Director	Jul 25 '25	Buy	29.90	267,556	7,999,924	454,982	Jul 30 04:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMA

ImageneBio Inc

Upgrade your Finviz experience